total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment the specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder the activity of the specific compound employed the specific composition employed the age body weight general health sex and diet of the patient the time of administration route of administration and rate of excretion of the specific compound employed the duration of the treatment drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts the total daily inhibitory dose of the compounds of this invention administered to a subject in single or in divided doses can be in amounts for example from 0 01 to 50 mg kg body weight or more usually from 0 1 to 25 mg kg body weight single dose compositions may contain such amounts or submultiples thereof to make up the daily dose in general treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound s of this invention per day in single or multiple doses in yet another embodiment the compounds of the invention may be used for the treatment of hcv in humans in monotherapy mode or in a combination therapy e g dual combination triple combination etc mode such as for example in combination with antiviral and or immunomodulatory agents examples of such antiviral and or immunomodulatory agents include ribavirin from schering plough corporation madison n j and levovirin from icn pharmaceuticals costa mesa calif.